{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(1)"],"submitter":["Hatletvedt ND"],"funding":["University of Bergen"],"pubmed_abstract":["<h4>Background</h4>Functional polymorphisms in the MDM2 promoters have been linked to cancer risk and several non-malignant conditions. Their potential role in bone marrow function during chemotherapy is largely unknown.<h4>Methods</h4>We investigated the potential associations between genotypes of MDM2 SNP309 (rs2279744), SNP285 (rs117039649) and del1518 (rs3730485) and neutrophil counts in breast cancer patients receiving neoadjuvant sequential epirubicin and docetaxel, with additional G-CSF, in the DDP-trial (NCT00496795). We applied longitudinal ratios, post vs. pre-treatment, of neutrophil counts as our main measure. Differences by genotypes were tested by Jonckheere-Terpstra test for ranked alternatives, while dominant and recessive models were tested by Mann-Whitney U test, and addi"],"journal":["BMC cancer"],"pagination":["308"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11843751"],"repository":["biostudies-literature"],"pubmed_title":["The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy."],"pmcid":["PMC11843751"],"pubmed_authors":["Lonning PE","Geisler J","Aas T","Engebrethsen C","Hatletvedt ND","Geisler S","Knappskog S","Gansmo LB"],"additional_accession":[]},"is_claimable":false,"name":"The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy.","description":"<h4>Background</h4>Functional polymorphisms in the MDM2 promoters have been linked to cancer risk and several non-malignant conditions. Their potential role in bone marrow function during chemotherapy is largely unknown.<h4>Methods</h4>We investigated the potential associations between genotypes of MDM2 SNP309 (rs2279744), SNP285 (rs117039649) and del1518 (rs3730485) and neutrophil counts in breast cancer patients receiving neoadjuvant sequential epirubicin and docetaxel, with additional G-CSF, in the DDP-trial (NCT00496795). We applied longitudinal ratios, post vs. pre-treatment, of neutrophil counts as our main measure. Differences by genotypes were tested by Jonckheere-Terpstra test for ranked alternatives, while dominant and recessive models were tested by Mann-Whitney U test, and addi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-06-01T13:01:39.344Z","creation":"2025-04-04T01:12:05.729Z"},"accession":"S-EPMC11843751","cross_references":{"pubmed":["39979836"],"doi":["10.1186/s12885-025-13675-2"]}}